novel
coronaviru
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
identifi
caus
agent
sar
profil
specif
antibodi
individu
protein
viru
critic
develop
vaccin
diagnost
tool
studi
recombin
protein
associ
four
structur
protein
e
n
five
put
uncharacter
protein
sarscov
prepar
use
screen
monitor
specif
igg
antibodi
sar
patient
sera
protein
microarray
antibodi
protein
n
detect
sera
convalescentphas
sar
patient
wherea
protein
e
undetect
detect
specif
antibodi
anti
antin
domin
could
persist
sera
sar
patient
week
among
rabbit
antisera
recombin
protein
n
serum
show
signific
neutral
activ
sarscov
infect
vero
cell
result
suggest
anti
antin
antibodi
diagnost
marker
particular
immunogen
therefor
good
candid
subunit
vaccin
antigen
viru
structur
viewpoint
presenc
human
sera
antibodi
react
two
recombin
polypeptid
support
hypothesi
synthes
viru
cycl
outbreak
atyp
pneumonia
first
emerg
guangdong
provinc
china
term
sever
acut
respiratori
syndrom
sar
world
health
organ
rapidli
spread
mani
region
countri
late
earli
thousand
peopl
got
infect
hundr
claim
novel
coronaviru
sar
coronaviru
sarscov
identifi
caus
agent
sar
sinc
viru
novel
pathogen
human
mani
aspect
remain
unknown
accur
diagnost
tool
protect
vaccin
play
indispens
role
control
genom
sarscov
predict
encod
replicas
structur
protein
includ
spike
glycoprotein
protein
envelop
glycoprotein
e
protein
membran
protein
protein
nucleocapsid
protein
n
protein
put
uncharacter
protein
although
put
uncharacter
protein
found
known
coronavirus
possibl
present
play
certain
function
sarscov
exampl
uniqu
novel
protein
sarscov
identifi
character
recent
humor
immun
one
immun
respons
defens
viral
infect
henc
investig
human
immun
respons
pathogen
provid
us
import
inform
mechan
pathogen
interact
host
understand
humor
immun
sarscov
li
et
al
studi
profil
specif
igg
igm
antibodi
sar
patient
sera
indirect
elisa
found
specif
igg
antibodi
present
test
convalesc
patient
sera
persist
long
time
week
specif
igm
antibodi
remain
measur
much
shorter
period
suggest
igg
antibodi
sarscov
may
repres
primari
humor
immun
respons
protect
patient
sar
although
sever
articl
publish
antibodi
respons
structur
protein
sarscov
contribut
protect
immun
extens
studi
profil
specif
antibodi
individu
protein
sarscov
remain
uncov
could
help
us
understand
humor
immun
also
develop
specif
diagnost
tool
vaccin
protein
microarray
abil
detect
antibodi
parallel
wide
rang
potenti
applic
epidemiolog
research
vaccin
develop
diagnosi
allergi
autoimmun
infecti
diseas
mezzasoma
et
al
gener
protein
microarray
print
five
microbi
antigen
simultan
determin
specif
antibodi
human
sera
human
igg
igm
bound
print
antigen
detect
confoc
scan
microscopi
quantifi
intern
calibr
curv
determin
result
well
concord
elisa
suggest
feasibl
util
antigen
microarray
determin
specif
antibodi
human
sera
previou
studi
investig
antigen
n
protein
sarscov
protein
microarray
contain
differ
recombin
truncat
n
protein
human
igg
serial
concentr
print
onto
slide
act
intern
calibr
standard
fluoresc
intens
fi
valu
gave
good
linear
correl
human
igg
concentr
indic
fi
valu
could
use
assess
rel
level
specif
antibodi
captur
respect
antigen
microarray
present
studi
understand
profil
antibodi
individu
protein
sarscov
recombin
protein
associ
four
structur
protein
e
n
five
put
uncharacter
protein
viru
prepar
use
screen
monitor
specif
igg
antibodi
sar
patient
sera
use
protein
microarray
rabbit
antisera
recombin
protein
aa
n
full
length
aa
full
length
prepar
use
investig
neutral
activ
sarscov
infect
vero
cell
sarscov
strain
use
studi
isol
anoth
group
institut
isol
genbank
access
number
passag
vero
cell
gener
viru
stock
titer
tissu
cultur
infect
dose
tcid
per
ml
work
infecti
viru
perform
insid
biosafeti
cabinet
biosafeti
level
laboratori
total
sera
collect
sar
patient
convalescentphas
beij
confirm
presenc
antisarscov
igg
antibodi
elisa
kit
whole
viru
lysat
coat
antigen
beij
gbi
biotechnolog
group
serial
sera
also
collect
recov
patient
week
onset
sar
guangdong
provinc
normal
human
sera
collect
healthi
peopl
year
sar
outbreak
human
sera
inactiv
min
sarscov
cultur
vero
cell
co
h
supernat
medium
infect
cell
collect
crude
sarscov
viru
viral
rna
extract
purifi
qiaamp
viral
rna
mini
kit
qiagen
cdna
synthesi
perform
superscript
ii
system
invitrogen
use
gene
specif
primer
amplif
full
length
truncat
fragment
four
structur
protein
five
put
uncharacter
protein
tabl
perform
pcr
sequenc
primer
refer
posit
within
correspond
gene
note
end
forward
revers
primer
contain
bamh
ecor
nco
site
sal
xho
bamh
site
respect
facilit
clone
amplifi
product
purifi
montag
pcr
kit
millipor
digest
specif
restrict
enzym
promega
ligat
plasmid
vector
novagen
use
dna
ligas
promega
final
transform
escherichia
coli
e
coli
strain
novagen
posit
recombin
clone
first
identifi
pcr
confirm
enzymat
cut
sequenc
recombin
bacteria
grown
optic
densiti
nm
luriabertani
medium
ampicillin
final
concentr
induc
mmoll
isopropylbdthiogalactosid
iptg
h
express
recombin
fusion
protein
purifi
use
ninta
agaros
qiagen
follow
manufactur
instruct
purifi
protein
dialyz
pb
ph
overnight
quantifi
spectrophotomet
beckman
howev
insolubl
protein
dissolv
moll
urea
purif
renatur
refold
solut
mmoll
tri
cl
ph
mmoll
larginin
mmoll
edta
mmoll
urea
mmoll
glutathion
oxid
mmoll
glutathion
reduc
least
h
dialysi
quantif
purifi
fusion
protein
dissolv
glycerolpb
solut
concentr
print
approxim
pl
triplic
onto
aldehyd
glass
slide
cel
associ
use
gsi
flexi
array
genom
solut
inc
human
igg
lysat
e
coli
print
onto
slide
posit
neg
control
respect
print
slide
store
overnight
use
within
week
print
serum
sampl
absorb
lysat
e
coli
carri
elimin
correspond
antibodi
serum
reaction
protein
slide
slide
first
block
nonfat
milk
pb
h
dilut
absorb
sera
ad
onto
slide
cover
coverslip
follow
h
incub
room
temperatur
slide
rins
three
time
min
pbst
pb
pb
twice
probe
captur
human
igg
dilut
goatantihuman
igg
goatantihuman
igg
label
dye
use
antibodi
label
kit
amersham
bioscienc
appli
slide
use
incub
condit
rins
protocol
describ
slide
spun
dri
prior
scan
nm
use
genepix
person
microarray
scanner
axon
instrument
fi
valu
spot
taken
subtract
median
intens
local
background
spot
util
genepix
pro
softwar
provid
compani
triplic
spot
signal
protein
averag
readi
analysi
sampl
analyz
three
time
one
new
zealand
white
rabbit
immun
recombin
fusion
protein
aa
n
full
length
aa
full
length
respect
mg
protein
ml
pb
emulsifi
equal
volum
freund
complet
adjuv
rabbit
immun
subcutan
inject
week
booster
protein
emulsifi
freund
incomplet
adjuv
given
subcutan
inject
follow
anoth
intraven
inject
protein
alon
anoth
week
antisera
collect
day
last
boost
immunoreact
titer
monitor
doubl
agar
diffus
precipit
perform
agaros
pb
twofold
serial
dilut
heatinactiv
antiserum
immun
rabbit
test
microneutr
assay
presenc
antibodi
neutral
infect
tcid
sarscov
vero
cell
monolay
four
well
per
dilut
plate
presenc
viral
cytopath
effect
read
day
dilut
serum
complet
prevent
cytopath
effect
well
calcul
reedmuench
formula
besid
encod
replicas
genom
sarscov
predict
encod
four
structur
protein
put
uncharacter
protein
number
predict
open
read
frame
orf
encod
put
uncharacter
protein
differ
public
depend
analysi
method
use
studi
clone
express
five
put
uncharacter
protein
larger
amino
acid
accord
predict
qin
et
al
four
structur
protein
tabl
posit
recombin
clone
confirm
dna
sequenc
among
express
protein
protein
express
five
truncat
fragment
includ
aa
aa
aa
aa
aa
protein
n
express
full
length
protein
e
express
truncat
fragment
full
length
could
express
vector
e
coli
express
level
low
recombin
protein
express
nh
molecular
weight
predict
fig
shown
express
protein
two
form
solubl
e
n
insolubl
solubl
protein
purifi
nativ
condit
use
ninta
agaros
insolubl
one
purifi
denatur
condit
renatur
dialysi
quantif
thirteen
recombin
protein
print
triplic
onto
glass
slide
protein
microarray
screen
specif
igg
antibodi
sera
convalescentphas
sar
patient
sera
healthi
peopl
control
fi
valu
protein
n
sera
sar
patient
statist
significantli
healthi
peopl
p
use
spss
softwar
fig
fi
valu
protein
e
sera
sar
patient
signific
differ
healthi
peopl
p
establish
baselin
assay
cutoff
valu
protein
calcul
use
fi
valu
protein
normal
human
sera
cutoff
mean
cutoff
valu
specif
protein
microarray
antibodi
detect
protein
n
correspond
sensit
five
truncat
recombin
protein
show
differ
immunoreact
patient
sera
among
could
react
almost
sampl
indic
sensit
antigen
detect
anti
antibodi
one
sampl
miss
antibodi
detect
fig
combin
result
anti
antibodi
present
patient
sera
order
investig
kinet
igg
antibodi
recombin
protein
n
human
onset
sar
group
serial
sera
collect
peopl
week
analyz
antin
antibodi
posit
serum
sampl
wherea
antibodi
posit
part
sampl
fig
show
antin
antibodi
persist
week
level
rapidli
increas
week
decreas
week
week
averag
fi
valu
half
week
addit
antibodi
remain
low
level
although
regret
could
obtain
patient
sera
week
avail
data
provid
us
valuabl
inform
help
screen
diagnost
marker
develop
vaccin
immun
protocol
antisera
gener
immun
new
zealand
white
rabbit
recombin
fusion
protein
n
respect
immunoreact
titer
respect
recombin
protein
less
use
doubl
agar
diffus
precipit
tabl
antisera
heatinactiv
dilut
serial
twofold
test
neutral
activ
infect
tcid
sarscov
vero
cell
serum
show
signific
neutral
activ
sarscov
infect
neutral
antibodi
titer
wherea
antisera
control
serum
nonimmun
rabbit
lack
neutral
antibodi
tabl
compar
elisabas
assay
protein
microarray
advantag
parallel
miniatur
thirteen
recombin
protein
appli
analyz
human
sera
control
patient
sera
band
indic
averag
fi
valu
protein
sera
healthi
peopl
convalescentphas
sar
patient
respect
cutoff
valu
calcul
data
healthi
peopl
cutoff
mean
indic
statist
signific
differ
patient
sera
control
high
throughput
detect
antibodi
studi
recombin
protein
associ
four
structur
protein
e
n
five
put
uncharacter
protein
sarscov
express
e
coli
use
screen
specif
igg
antibodi
convalescentphas
sar
patient
sera
protein
microarray
antibodi
protein
n
detect
differ
posit
rate
n
structur
protein
present
sarscov
known
coronaviru
number
research
group
report
specif
antibodi
n
could
detect
sar
patient
sera
predict
protein
sarscov
found
known
coronaviru
serolog
evid
impli
two
uniqu
novel
protein
may
actual
present
sarscov
complet
manuscript
protein
identifi
character
laboratori
group
respect
antibodi
also
known
also
detect
sar
patient
sera
howev
possibl
presenc
novel
protein
consist
amino
acid
residu
sarscov
need
prove
hand
signific
antibodi
protein
e
detect
test
sera
protein
e
structur
protein
sarscov
result
indic
may
induc
antibodi
product
human
antibodi
concentr
may
low
detect
anoth
possibl
reason
could
rule
bacteria
express
protein
fold
posttransl
modifi
correctli
recogn
correspond
antibodi
similar
result
protein
e
also
known
could
seen
newli
publish
paper
tan
et
al
express
full
length
protein
e
mammalian
cell
total
protein
lysat
analyz
western
blot
sera
three
convalescentphas
sar
patient
antibodi
protein
detect
far
serolog
diagnosi
sar
reliabl
laboratori
method
contrast
whole
virusbas
assay
recombin
proteinbas
assay
advantag
safeti
economi
sever
research
group
evalu
possibl
use
recombin
protein
n
andor
serolog
diagnosi
past
year
antin
prove
frequent
antibodi
sar
patient
bacteria
express
n
protein
even
truncat
n
protein
highli
immunogen
although
anti
antibodi
detect
convalescentphas
sera
immunofluoresc
mammalian
cell
express
protein
detect
sar
patient
sera
western
blot
bacteria
express
protein
detect
convalescentphas
sera
western
blot
bacteria
express
protein
aa
present
studi
use
protein
microarray
qualit
quantit
screen
serolog
diagnost
marker
among
detect
antibodi
protein
n
antin
domin
respect
posit
rate
highlevel
fi
valu
respect
convalescentphas
sar
patient
sera
even
sampl
miss
detect
indic
antin
anti
antibodi
sensit
diagnost
marker
sarscov
infect
bacteri
express
recombin
protein
n
aa
could
use
antibodi
detect
howev
detect
respect
sera
lowlevel
fi
valu
respect
suggest
limit
use
two
antibodi
diagnost
marker
sarscov
infect
immun
one
sarscov
subunit
antigen
either
administ
purifi
protein
express
viral
dna
vaccin
vector
one
approach
design
vaccin
sar
approach
would
facilit
knowledg
rel
import
variou
viral
structur
protein
induc
protect
immun
present
studi
rabbit
antisera
recombin
fusion
protein
aa
n
full
length
aa
full
length
test
neutral
activ
infect
tcid
sarscov
vero
cell
serum
show
signific
neutral
activ
sarscov
infect
neutral
antibodi
titer
suggest
protein
neutral
antigen
sarscov
recombin
protein
aa
may
use
candid
subunit
vaccin
although
antin
antibodi
also
present
sar
patient
sera
highlevel
persist
long
time
week
recombin
n
protein
could
induc
detect
neutral
antibodi
rabbit
sarscov
infect
paper
sarscov
vaccin
studi
among
structur
protein
could
induc
protect
immun
experiment
anim
exampl
buchholz
et
al
investig
contribut
structur
protein
e
n
sarscov
protect
immun
express
individu
combin
recombin
parainfluenza
viru
piv
type
vector
call
tabl
immunoreact
neutral
activ
rabbit
antisera
recombin
protein
sarscov
immunoreact
titer
neutral
antibodi
titer
b
n
nonimmun
control
serum
titer
antibodi
react
respect
recombin
protein
use
doubl
agar
diffus
precipit
titr
reciproc
valu
last
dilut
properti
observ
b
titer
antibodi
neutral
infect
tcid
sarscov
use
microneutr
assay
titr
reciproc
valu
last
dilut
serum
complet
prevent
cytopath
effect
well
calcul
reedmuench
formula
evalu
recombin
immunogen
protect
efficaci
hamster
result
identifi
protein
among
structur
protein
signific
neutral
antigen
show
singl
mucos
immun
highli
protect
experiment
anim
support
effici
replic
sarscov
protein
promis
develop
diagnost
antigen
vaccin
antigen
five
truncat
recombin
fusion
protein
preliminarili
analyz
studi
anti
antibodi
detect
convalescentphas
sar
patient
sera
use
either
sequenc
individu
express
aa
aa
form
whole
sequenc
protein
two
recombin
protein
react
patient
sera
respect
although
sequenc
cover
aa
much
sensit
detect
patient
sera
suggest
import
epitop
appear
conform
addit
aa
aa
could
react
sampl
miss
antibodi
suggest
one
import
epitop
may
present
overlap
sequenc
aa
work
done
full
antigen
analysi
protein
elucid
epitop
diagnost
antigen
vaccin
develop
